Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2509-4254
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer ; volume:6 ; number:6 ; day:15 ; month:9 ; year:2022 ; pages:899 ; date:11.2022
PharmacoEconomics - open ; 6, Heft 6 (15.9.2022), 899, 11.2022
- Urheber
-
Elsea, David
Fan, Lin
Mihai, Adela
Moustaid, Fadoua El
Simmons, Daniel
Monberg, Matthew
Muston, Dominic
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s41669-022-00372-0
- URN
-
urn:nbn:de:101:1-2023011021070395277738
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Elsea, David
- Fan, Lin
- Mihai, Adela
- Moustaid, Fadoua El
- Simmons, Daniel
- Monberg, Matthew
- Muston, Dominic
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
Olaparib (Ovarialkarzinom; Erstlinie Erhaltung in Kombination mit Bevacizumab) : Addendum zum Auftrag A20-111
Olaparib (Ovarialkarzinom; Erstlinie Erhaltung in Kombination mit Bevacizumab) : Nutzenbewertung gemäß § 35a SGB V
Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Bevacizumab for patients with recurrent multifocal glioblastomas
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
Vitreous changes after intravitreal bevacizumab monotherapy for retinopathy of prematurity: a case series
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
Olaparib (Ovarialkarzinom; Erstlinie Erhaltung in Kombination mit Bevacizumab) : Addendum zum Auftrag A20-111
Olaparib (Ovarialkarzinom; Erstlinie Erhaltung in Kombination mit Bevacizumab) : Nutzenbewertung gemäß § 35a SGB V
Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Bevacizumab for patients with recurrent multifocal glioblastomas
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
Vitreous changes after intravitreal bevacizumab monotherapy for retinopathy of prematurity: a case series
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
Olaparib (Ovarialkarzinom; Erstlinie Erhaltung in Kombination mit Bevacizumab) : Addendum zum Auftrag A20-111
Olaparib (Ovarialkarzinom; Erstlinie Erhaltung in Kombination mit Bevacizumab) : Nutzenbewertung gemäß § 35a SGB V
Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Bevacizumab for patients with recurrent multifocal glioblastomas
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
Vitreous changes after intravitreal bevacizumab monotherapy for retinopathy of prematurity: a case series